In recent years, the treatment of skin immune diseases (such as psoriasis, urticaria, etc.) has entered the era of precision due to the breakthrough of biological agents, which has significantly improved the skin lesion clearance rate and quality of life of patients. However, there are still many clinical challenges in the pharmaceutical mechanism analysis, safe drug use norms and long-term patient management of biological agents. In order to promote interdisciplinary collaboration and diagnosis and treatment innovation, Chengdu high tech Medical Association held the "joint diagnosis and treatment exchange meeting of psoriasis and arthritis" online on May 27, 2025, inviting authoritative experts in the field to discuss cutting-edge issues. The meeting focused on the mechanism of biological agents in psoriasis and arthritis, and combined with the latest research data, analyzed the formulation of individualized medication plan and long-term safety monitoring strategy. Experts shared cases of synergy between biological agents and traditional therapies, emphasizing the clinical value of the "precise targeting + whole process management" model. This exchange meeting aims to build an interdisciplinary communication platform, promote the precise and safe application of biological agents, and provide better whole process management solutions for patients with skin immune diseases.